Embed Size (px)
DESCRIPTION
Innovate in an era of cost-effectiveness: Realise the value of personalised medicine • How is your business model evolving? Transform from Blockbuster to Nichebuster • Discover how to strengthen your drug pipeline with companion diagnostics • How to access the market • Hear about the expectation of the pharmaceutical and diagnostics industry and payors • Discover how pharmaceutical companies and diagnostics companies can work together successfully Powerful reasons to attend the event: Get the latest information on personalized medicine at your fingertips. With access to exclusive keynote sessions and a very focused agenda, you’ll gain more in just 2 days than from weeks of market research or by purchasing expensive reports. Expert speakers from Roche, Merck, Biomerieux, NICE, Pfizer and GSK will share their vision and best practice case studies. You can really profit from their knowledge and create powerful new strategies to overcome your business challenges. Unrivalled networking. Claim your seat at the table with all the key industry decision-makers and thought leaders to ensure you leave this meeting with your briefcase full of valuable contacts. Plus benefit from a number of structured 1-1 meetings during the networking breaks. Senior level decision-makers in attendance. Rub shoulders with the leading executives in personalized medicine from the U.S. and around the world to give your commercial enterprise a truly global perspective. No sales pitches. Personalized Medicine & Diagnostics is an independently researched forum committed to equip you with the tools and expertise to drive your business forward. Every single presentation is rigorously reviewed to ensure an unrivalled high quality.
Citation preview
In AssocIAtIon wIth:
offIcIAl medIA pArtner: medIA pArtners:
3
3
3
3
3
3
How is your business model evolving? Transform from Blockbuster to Nichebuster
How to take advantage of the economic and business trends in personalised medicine
Strengthen your drug pipeline with companion diagnostics
Overcome the challenges in regulation and market access
Hear about the expectation of the pharmaceutical and diagnostics industry and payors
Discover how pharmaceutical companies and diagnostics companies can work together successfully
CONfereNCe
senior level executives from the most relevant sectors come together for exclusive keynote sessions, case reports and high level business discussions that will set the pace of future therapeutics.
TOPICS & SPeAKerS
we listen to what the industry wants. the program of the event was structured in conjunction with senior level executives to make it as applicable and useful as possible. the best qualified speakers will be sharing their knowledge and experience with you!
NeTwOrKINg
during the 12+ hours of dedicated networking, you’ll rub shoulders with the sharpest minds in the industry. no other event can provide you with 2 days of business focused networking with some of the most influential people in your field.
3 3 3
ExpErt SpEakErS
An excellent conference which delivered what it said on the tin!
JAmes clArkMDx Health
cAthArIne GoddArd, principal translational scientist, Pfizer
AndreA rAppAGlIosI Vice president european Government Affairs,
gSK and president,
europaBio
hAns wInkler senior director, head of oncology Biomarker development, ortho Biotech oncology,
Johnson and Johnson Pharmaceutical
IAIn d. mIllerexecutive director, theranostics strategy and Business development,
Biomerieux
Glyn coleBrookesenior director, Business development,
Philips
nIck crABBAssociate director, diagnostics Assessment programme
Centre for Health Technology evaluation, NICe
AdAm heAthfIelddirector science policy,
Pfizer
Good meeting, perfect number of delegates, excellent discussion and interactions
pErSonaliSEd MEdicinE & diagnoSticS EuropE9-10 March 2011, novotel london St. pancras, uk
europe’s premier meeting that brings together the pharmaceutical and diagnostics industry
innovate in an era of cost-effectiveness: realise the value of personalised medicine
orGAnIsed & reseArched By Save € 200WhEn you rEgiStEr bEforE
28th January 2011
welcome to personalised medicine & diagnostics europe
our global business intelligence has revealed widespread
pressure to streamline, increase operational output and
reduce costs. the pharmaceutical industry has received
a call to action! translating findings across the value
chain and sub-grouping patients can deliver proven
roI, and is the biggest area of growth in the healthcare
sector. so what’s holding personalised medicine back and when will mass adoption become a reality?
In 2011, we have produced an agenda that will prepare
you for the new era of personalised medicines. It has
been described as do-or-die for the pharma industry by
some experts.
I have invited the most forward-thinking leaders from
the industry to discuss the roadmap to a strong industry
growth. take a look at some key discussion points in 2011:
3Analysis of the personalised medicine market in
europe and globally
3find out what the value of companion diagnostics is
3learn how to overcome market access hurdles for
personalised medicines and companion diagnostics
Dear Colleague …3find out who “big pharma” is partnering with and why
3showcase of latest technology
As diagnostics expert who wants to diversity your prod-
uct portfolio and take advantage of this fast growing
sector you will find out how to partner with pharma-
ceutical companies and what they are looking for.
Personalised Medicine & Diagnostics europe boasts of:
3expert personalised medicine speakers from pharma,
biotech, diagnostics and regulatory agencies will
provide cutting-edge strategies and market intelligence
3they will discuss successful and failed cases to
give you the toolkit for your successful product
development
3meet the companies that are looking for partner-
ships and discover how you can work together
3meet new solution providers who will present their
developments and technologies that help you with
your challenging problems
3Unparallel networking is the icing on the cake!
personalised medicine & diagnostics europe is a land-
mark on the industry calendar and a priority for all
professionals serious about the future of drug develop-
ment with companion diagnostics.
Personalised Medicine & Diagnostics europe is the only event you’ll need to attend in 2011!so secure a front row seat for an unobstructed view of
the future of the pharmaceutical industry! reserve your
place today (via our website or the registration form en-
closed in this brochure).
I look forward to meeting you in london this march.
yours,
JohAnnes stAntA
Ph.D., Vice President,
eyeforpharma
expert speakers include:
Andrea rappagliosiVice president european Government Affairs,
gSK and president
europaBio
charles swantonph.d., head translational cancer
therapeutics, Cancer research UK
louise leongph.d., head of r&d, Association of the British
pharmaceutical Industry, ABPI
Iain d. millerexecutive director, theranostics strategy and
Business development,
Biomerieux
michael motzph.d., director,
Business development and partnering,
roche
Gabriel Vargasm.d., ph.d., Biomarker expert at
Hoffmann-La roche
& head of the CNS Clinical Biomarker group
matthew w. Beerph.d., managing director oncology marketing,
Quest Diagnostics
hans winkler ph.d., senior director, head of oncology Biomarker
development, ortho Biotech oncology,
Johnson and Johnson Pharmaceutical r&D
eddie Blairph.d., managing director,
Integrated Medicines
stefan müllnerph.d., ceo,
Protagen Ag
Ansar Jawaidph.d., Global diagnostics Brand manager,
Global commercial,
AstraZeneca
paolo morgeseAssociate director, market Access,
MerckSerono
James clarkph.d., Vice president research and development,
MDx Health
Angela flanneryph.d., director, r&d science policy
AstraZeneca
pietro scalfaroph.d., director of Business Unit diagnostics,
Debiopharm
Glyn colebrookesenior director Business development
Philips
John lambertmBBs, ph.d, mmed, mfpm, frAcp, Vice president
chief medical officer early phase clinical Unit,
Parexel
david Gonzalez de castroph.d., head of molecular diagnostics,
The royal Marsden Hospital and The Institute of
Cancer research
Alexander natzll.m., secretary General, eUcope and head
of Brussels office, Bundesverband der
Pharmazeutischen Industrie e.V. (BPI)
nick crabbph.d., Associate director, diagnostics Assessment
programme, centre for health technology
evaluation, NICe (national Institute for health and clinical excellence)
Adam heathfieldph.d., director science policy
Pfizer
for the full speaker line-up and the most up to date information visit www.eyeforpharma.com/personalisedmedicine
personalised medicine & diagnostics europe at a Glance
1-2-1 COLLABOrATION MeeTINgS
CONfereNCe
Personalised Medicine & Diagnostics europe, 9th - 10th March, Novotel London St. Pancras, UK
3
3New fOr 2011
A best practice guide on integrating diagnostics in the drug development process
companies that are looking for partnerships
the best speakers from the industry
All vital industry topics
more case studies about the good and the bad
what diagnostics companies need to provide to be seen a great partner for the pharmaceutical industry networking with all key industry players in personalised medicine and companion diagnostics
In addition to providing a programme that is designed to give delegates plenty of information that will help them solve their business challenges, the event will also include an option for delegates to take part in a number of structured 1:1 ‚matchmaker‘ or collaboration meetings.
3
3
333
3
3
NeTwOrKINg AND exHIBITION
face-to-face networking is key to survival in 2011. you’ll rub shoulders with the sharpest minds in r&d during the 12+ hours of dedicated networking. no other event can provide you with 2 days of business focused networking with some of the most influential people in your field. Build relationships and grow your contact list in 2011 to transform the future of your business.
the personalised medicine & diagnostics exhibition floor is an opportunity to see, discover and understand new products and solutions in action. spaces are limited. Get in touch today with richar ellis on +44 20 7375 7170 or [email protected] to secure your place.
3
The only exhibition floor you’ll need
DAy ONe – 9th mArch 2011
MOrNINg OPeNINg KeyNOTe AND PLeNAry SeSSIONShear where the industry is moving and get the latest updates
SeSSION 1: PerSONALISeD MeDICINe MArKeT OVerVIewexamine major trends and learn where to invest your efforts
- Networking Lunch -
SeSSION 2: INTegrATe COMPANION DIAgNOSTICS IN THe DrUg DeVeLOPMeNT PrOCeSS
- Networking Drinks Party -
SeSSION 3: BUSINeSS MODeLS THAT ACHIeVe THe DeVeLOP PerSONALISeD MeDICINe PrODUCTSdiscover how to strengthen the drug pipeline with companion diagnostics and how this trends is becoming a necessity
- Networking Lunch -
SeSSION 4: ASSeSSINg, PrICINg AND reIMBUrSINg PerSONALISeD MeDICINefocus your efforts on the right areas and find out what the emA and health technology Assessment departments are expecting
- Closing Address -
DAy TwO – 10th mArch 2011
Good meeting, the per-fect number of delegates, excellent discussion and interactions.
JAmes clArk, MDx Health
Join our lively conference group on and become a part of the global buzz surrounding the conference.
sessIon 1:
Personalised medicine market overview
An initiative for stratified medicines
3 the future of personalised medicine in europe3 what is the Uk government plan to create an environment in which the industry can flourish and grow and how that will transform the european industry? 3 learn how public and private partnership could lead to an integrated approach to tackle the issues of uptake and reimbursement
Angela flannery, ph.d., director, research and development science policy, AstraZeneca
sessIon 2:
Integrate companion diagnostics in the drug development process
provide efficient molecular diagnostics and molecular pathology service for cancer patients
3 learn what is required to implement molecular diagnostics in the clinic3 the challenges of molecular diagnostics in routine real-life practice in the Uk and how the royal marsden hospital has found solutions in a wide port folio of personalised cancer medicines3 the future directions of molecular pathology and clinical trials. horizon mapping
david Gonzalez de castro, ph.d., head of molecular diagnostics, The royal Marsden Hospital and The Institute of Cancer research (ICr)
overcome challenges in cancer medicine biomarker discovery
3 discover the reasons for limited examples of pre- dictive biomarkers in oncology practice and how to overcome this 3 discuss how functional genomics can be integrated with parallel clinical trials to accelerate biomarker discovery 3 the major challenges to personalised medicine and predictive biomarker discovery in cancer research – can a multi-disciplinary collaborative approach address this?
charles swanton, ph.d., head translational cancer therapeutics, Cancer research UK
Accelerate drug development through confident and data-based decision making
3 Increase likelihood of clinical benefit: experiences and strategies in data-driven patient selection based on predictive biomarkers.3 Best ways to master the critical issue in the devel- opment process: assessing clinical efficacy of novel medicines early.3 discuss the key factors in translational science for an efficient diagnostics co-development
hans winkler, ph.d., senior director oncology Biomarkers, Janssen Pharmaceutical Companies of Johnson & Johnson
how to use biomarkers in early clinical drug development to support person-alised medicine strategy
3 Identify the key factors for translational science in diagnostics development3 learn to use the best strategies to maximise the value of biomarkers and strengthen your develop- ment pipeline3 hear about successful cases in molecular diagnos- tics and how to move from technologies to treatments
John lambert, mBBs, ph.d, mmed, mfpm, frAcp, Vice president chief medical officer early phase clinical Unit, Parexel
digital histopathology stratified medi-cine and robust companion diagnostics.
3 Assessment of tissue architecture as the entry point for personalising cancer treatment3 discover how digital management of histopatho- logy images introduces the opportunity to improve accuracy, collaboration, reporting and archiving3 new digital systems allow for automated high throughput histopathology on a platform that have a straightforward journey from discovery to clinical practice
Glyn colebrooke, senior director Business development, Philips
Using autoantibodies in companion diagnostics
3 Autoantibodies vs. genomic based markers in patient stratification and therapy selection: the superiority debate3 A new concept: Autoantibody signatures for the development and validation of dx and cdx marker panels
stefan müllner, ph.d., ceo, Protagen
the role of efficacy biomarkers in drug-diagnostics co-development programs
3 how to strengthen the drug pipeline with companion diagnostics and how this trends is becoming a necessity3 discuss the challenges of companion diagnostics development in central nervous system diseases and how to approach them
Gabriel Vargas, m.d., ph.d., Biomarker expert & head of the cns clinical Biomarker Group, Hoffmann-La roche
dnA methylation patterns in cancer research and the use in companion diagnostics
3 learn about the challenges in cancer analytics and diagnostics development and how mdx health is addressing these3 discuss how dnA methylation in cancer discovery and prediction can overcome common problems in pharmacogenomics
James clark, ph.d., Vice president research and development, MDx Health
sessIon 3:
Business models that achieve the development of personalised medicine products
deliver personalised medicines to the patient
3 learn how to develope and deliver a global diag- nostic strategy on the example of Astrazeneca’s oncology drugs3 discuss practical initiatives that have driven diagnostic testing3 find out how to meet the needs of different countries to successfully launch a personalised medicine globally
Ansar Jawaid, ph.d, Global diagnostics Brand manager, global Commercial, AstraZeneca
day 1: wednesday march 9th 2011
successful strategies in personalised medicine: learnings from a global IVd company
3 discover the strategic perspective on the personal- ised medicine market from an IVd viewpoint3 discuss successful co-development and alliance management models in cancer and infectious disease3 Gain inisight into how Biomerieux made successful partnerships with Gsk, merck, Ipsen, and transgene to mutually benefit all stakeholders
Iain d. miller, ph.d., executive director, theranostics strategy and Business development, Biomerieux
the evolution of an alternative business model in the pharmaceutical industry
3 Identify the key factors for moving from technolo- gies to treatments to stay at the forefront of the industry3 learn about the emerging diagnostics areas to focus your efforts in the areas with the highest potential3 discuss cases of pre-and post-approval collabo- rations to make evidence based decisions in your partnering strategies
matthew w. Beer, ph.d., director oncology marketing, Quest Diagnostics
how to ensure long term success in delivering personalised medicine
3 Investigate best strategies for the co-development of drugs and diagnostics and hear what has worked and what hasn’t3 partnership trends in the industry and what roche is looking for in a strategic partner and diagnostics co-developer
michael motz, ph.d., director, Business development and partnering, roche
personalised medicine in a era of cost-effectiveness
3 what are the challenges in adding diagnostics to clinical practice and do medicines developers benefit from it?3 discuss the importance of diagnostics for commer- cial and research success3 what pfizer has learned from personalised medicine experiences to date and the impact on research, cost, time of development and commercialisation
Adam heathfield, ph.d., science policy director, Pfizer
sessIon 5:
Make partnering work across the industry
how to effectively interface molecular diagnostic during drug development to prepare for personalised medicine
3 Best ways to find key capabilities to make optimal and evidence based decisions3 pitfalls of data-based decision making and using quality of data over quantity3 how to manage the partnering expectations to ensure shared vision and values and to get the right balance of time, quality and cost
pietro scalfaro, m.d., director Business Unit diagnostics, Debiopharm group
work on an unified strategy for personalised medicine
3 learn how the formation of new r&d partnerships has transformed the outlook for personalised medicine in the Uk3 Get a deep dive and analysis of partnerships that have been consummated3 hear about the role of clusters in fostering partner ship in personalised medicine, including case studies
louise leong, head of research and development, Association of the British Pharmaceutical Industry (ABPI)
sessIon 4:
The challenges of assessing, pricing and reimbursing personalised medicine
changes in the German market for pricing and reimbursement of innovative pharmaceuticals
3 learn who are the key players in the German market3 discover what will happen with the German htA and which impact the early benefit assessment under § 35a sGB V will have on your market access strategy.3 hear about the pitfalls in price negotiations and the impact of reference pricing
Alexander natz, ll.m., secretary General, eUcope and head of Brussels office, Bundesverband der Pharmazeutischen Industrie e.V. (BPI)
the nIce diagnostics assessment programme
3 learn about nIce and the new diagnostics Assessment programme3 discuss the methodology challenges in the assess- ment of clinical and cost effectiveness of diagnostic technologies3 hear about nIce’s view on the assessment of companion diagnostics
nick crabb, ph.d., Associate director, diagnostics Assessment programme, National Institute for Health and Clinical excellence (NICe)
the european policy agenda in personalised medicine
3 what is on the agenda of the european commission and how will it effect personalised medicine?3 focus your efforts on the right areas and find out what the emA and health technology Assessment departments have planned.3 can the transparency directive support the improvement of access to personalised medicine?
Andrea rappagliosi, Vp european Government Affairs & head of Brussels office, gSK. chair of the europaBio Healthcare Council
day 2: thursday march 10th 2011
philippe mourere, Caliper Life Sciences,(about personalised medicine Us 2010)
INTerACTIVe PANeL SeSSION:how to align business models and development time-lines between pharmaceutical and diagnostics companies3matthew w. Beer, ph.d., director oncology marketing, Quest Diagnostics3eddie Blair, ph.d., managing director, Integrated Medicines3Angela flannery, ph.d., director, research and development science policy, AstraZeneca
INTerACTIVe PANeL SeSSION:what constitutes value in a companion diagnostic?
3Anne Bruinvels, ph.d., executive director, european Personalised Medicine Association3nick crabb, ph.d., Associate director, Diagnostics Assessment Programme, NICe3paolo morgese, Associate director, market Access, MerckSerono
The speakers selection was great - covered the promises and challenges of personalised medicine strategies in the discovery and diagnostic areas.
knoW Who you’ll bE rubbing ShouldErS With in March 2011
Attendees by Industry sector:
Industry sectors: Pharmaceutical, biotech, diagnostic
Top reasons to become a sponsor of Personalised Medicine & Diagnostics today!
SPLIT By SeCTOr: SPLIT By JOB TITLe:
key reasons why you can’t miss the conference
Industry (pharmaceutical, Biotechnology &
diagnostics)
63%
director
26%
head
21%
technology
provider/cro
15%
Academia
14%
other
8%
3promote your technology in a show-case presentation or a full speaking slot and be part of the program 3sign up now to secure the best booth on the expo floor and give your products and services the competitive edge.3meet directly with your best prospects and clients. personalised medicine & diagnostics europe is the event where industry leaders make informed decisions.3sign up early to capitalised on pre-event visibility via our network of key industry players to guarantee that everyone talks about you.3don’t forget that personalised medicine & diagnostics europe is the place where new relations are forged and partnerships start.3do the right thing for your company and book your space now before the exhibition space sells-out.
Business development
companion diagnostics
Biomarker research
research scientist
regulatory Affairs
health economics
personalised therapy
diagnostic development
new products & portfolio strategy
market Access
strategic partnering
scientific/medical Affairs
scientist/researcher
18%
manager
16%
ceo/president/Vice president
11%
consultant
5%
media
3%
who’s attending?
Join our dedicated LinkedIn group at www.linkedin.com
grOUP SeArCH: eyeforpharma Translational MedicineInnovation
contact richard ellis today to get your quote at [email protected] or +44 20 7375 7170
Staying in london?
SeLeCT PASS TyPe
three simple steps to register now!
head
21%
we want to invite you to extend your stay in london either before or after the summit, and you are more than welcome to bring a partner. we’ve negotiated special rates in the novotel st. pancras for you. for further information on how to book, visit the venue page on our websitewww.eyeforpharma.com/personalisedmedicine
PLATINUM PASS
3two day full access pass
3full event recordings
3report on personalised medicine
€ 1895 + VAt € 2095 + VAt € 2295 + VAt
gOLD PASS
3two day full access pass
3full event recordings
€ 1695 + VAt € 1895 + VAt € 2095 + VAt
SILVer PASS
3two day full access pass
€ 1495 + VAt € 1695 + VAt € 1895 + VAt
ACADeMIA AND gOVerNMeNT € 995 + VAt € 995 + VAt € 995 + VAt
PLATINUM PASS
3two day full access pass
3full event recordings
3report on personalised medicine
€ 2095 + VAt € 2295 + VAt € 2495 + VAt
gOLD PASS
3two day full access pass
3full event recordings
€ 1895 + VAt € 2095 + VAt € 2295 + VAt
SILVer PASS
3two day full access pass
€ 1695 + VAt € 1895 + VAt € 2095 + VAt
TerMS AND CONDITIONS places are transferable without any charge i.e. you can change the name of the attendee for free. cancellations before 9th february 2011 incur an administrative charge of 25%. If you cancel your registration after 9th february 2011 we will be obliged to charge you the full fee. please note - you must notify eyeforpharma in writing (email) of a cancellation, or we will be obliged to charge you the full fee.
the organizers reserve the right to make changes to the program without notice. All prices displayed are exclusive of tax unless otherwise stated. tax will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice. eyeforpharma takes every care to ensure that prices quoted are correct at time of publishing however, bookings will only be accepted if there is no material error in the price advertised on the website.
I enclose a check/draft for: (Payable to fC Business Intelligence)
Please invoice my company:
Mr/Mrs/Ms/Dr: first name: Last name:
Telephone: fax: email:
Company Position/Title:
Address: Postcode: Country:
Purchase Order number:
Please charge my credit card: Amex Visa Mastercard
Credit Card Number:
Name on card:
expiry date: Security number:
Signature:
fax this form back to +44 (0) 20 7375 7576
PHArMA, BIOTeCH & DIAgNOSTICS COMPANIeS
SOLUTION PrOVIDerS & CONSULTANTS
SUPer eArLy BIrD register by 17.12.2010
SUPer eArLy BIrD register by 17.12.2010
eArLy BIrD register by 28.01.2011
eArLy BIrD register by 28.01.2011
STANDArD PrICe
STANDArD PrICe
DISCOUNT CODe:
pErSonaliSEd MEdicinE & diagnoSticS EuropE9-10 March 2011, novotel london St. pancras, uk
europe’s premier meeting that brings together the pharmaceutical and diagnostics industry
orGAnIsed & reseArched By
industry buzz about eyeforpharma’s past personalised and translational medicine conferences:
powerful reasons to attend:
1
2
3
45
6 MONTH’S reSeArCH with executives from the top 20 pharma and diagnostics companies like pfizer, AstraZeneca, novartis, roche, Biomerieux have ensured we know exactly what yoU need to know when it comes to to succeeding in the growing market of personalised medicine.
exPerT SPeAKerS. the leading minds and key opinion leaders from roche, merck, Biomerieux, nIce, pfizer, Gsk will share their vision and best practice case studies. you can really profit from their knowledge and create powerful new strategies to overcome your business challenges.
UNrIVALLeD NeTwOrKINg. claim your seat at the table with all the key industry decision-makers and thought leaders to ensure you leave this meeting with your briefcase full of valuable contacts. plus benefit from a number of structured 1-1 meetings during the networking breaks.
SeNIOr LeVeL DeCISION-MAKerS IN ATTeNDANCe. rub shoulders with the leading executives in drug development from europe and around the world to give your commercial enterprise a truly global perspective.
NO SALeS PITCHeS. personalised medicine & diagnostics medicine is an independently researched forum committed to equip you with the tools and expertise to drive your business forward. every single presentation is rigorously reviewed to ensure an unrivalled high quality.
“An excellent conference which deli-vered what it said on the tin!” catharine Goddard, Pfizer
“Great event!”doina roman, Takeda global r&D
“An interesting meeting with good content and good networking opportunities”mads Almose røpke, LeO Pharma
“Well organised, high level and interesting programme. Good speakers.” elina serkkola, Orion Pharma
“Well worth the money”Jonathan sheldon, IDBS
4 EaSy WayS to rEgiStErCall +44 (0) 20 7375 7225fax +44 (0) 20 7375 7576email [email protected] www.eyeforpharma.com/ personalisedmedicine
In AssocIAtIon wIth: offIcIAl medIA pArtner: medIA pArtners:
“I appreciated the openness and interactivity of the sessions”Inge de lepeleire,
Merck Sharp & Dohme, Inc.
New fOr 2011In addition to providing a programme that is designed to give delegates plenty of information that will help them solve their business challenges, the event will also include an option for delegates to take part in a number of structured 1:1 collaboration meetings.
innovate in an era of cost-effectiveness: realise the value of personalised medicine
Save € 200WhEn you rEgiStEr bEforE
28th January 2011
